Which of the following statements about myositis are correct: a) Polymyositis presents with symmetric proximal muscle weakness, b) Inclusion body myositis involves symmetric involvement of the upper‑limb muscles, c) The anti‑Jo‑1 (anti‑histidyl‑tRNA synthetase) antibody is specific for idiopathic inflammatory myopathies, d) Idiopathic inflammatory myopathies can rarely be associated with malignancies?

Myositis Statements: Accuracy Assessment

Statement (a) is CORRECT, statement (c) is INCORRECT (anti-Jo-1 is not specific to IIM), statement (b) is INCORRECT (IBM shows asymmetric involvement), and statement (d) is INCORRECT (malignancy association is not rare, particularly in dermatomyositis).

Statement-by-Statement Analysis

a) Polymyositis presents with symmetrical proximal muscle weakness - CORRECT

Polymyositis is definitively characterized by symmetric proximal muscle weakness 1. This is a cardinal feature that develops over weeks to months and represents the classic presentation pattern. The Mayo Clinic guideline explicitly states that "Polymyositis (PM) is characterized by symmetric proximal muscle weakness" 1. This manifests clinically as:

• Difficulty holding arms overhead
• Trouble climbing stairs
• Inability to rise from a chair
• Progressive weakness affecting hip flexors, shoulder girdle muscles, and neck flexors bilaterally

The symmetry distinguishes polymyositis from inclusion body myositis and helps guide appropriate immunosuppressive therapy.

b) Inclusion body myositis involves symmetrical affection of upper limb muscles - INCORRECT

This statement is fundamentally wrong. Inclusion body myositis (IBM) is characterized by asymmetric weakness, not symmetric involvement 2. The pattern specifically affects:

• Quadriceps muscles (knee extensors) - often the earliest and most prominent feature
• Finger flexors (deep finger flexors and forearm muscles) - creating the characteristic "grip weakness"
• Asymmetric distribution is a defining feature

The asymmetric pattern, particularly the combination of quadriceps and finger flexor weakness, is pathognomonic for IBM and distinguishes it from polymyositis 2. This asymmetry is critical for diagnosis because IBM does not respond to immunosuppressive therapy like polymyositis does, making accurate differentiation essential for patient management and prognosis.

c) The anti-Jo-1 antibody is specific to idiopathic inflammatory myopathies - INCORRECT

While anti-Jo-1 antibodies are myositis-specific autoantibodies, they are not exclusive to IIM 3. Anti-Jo-1 is the most prevalent of the anti-synthetase antibodies and defines anti-synthetase syndrome, which encompasses:

• Myositis (but not always present)
• Interstitial lung disease
• Inflammatory arthritis
• Fever
• Raynaud's phenomenon
• Mechanic's hands

Critical distinction: Anti-Jo-1 can be present in patients who have interstitial lung disease, arthritis, and other features of anti-synthetase syndrome without having clinically evident myositis 3. The antibody defines a syndrome broader than just inflammatory myopathy. Additionally, myositis-specific autoantibodies "may define subgroups of patients with idiopathic inflammatory myositis" but are not absolutely specific to the muscle disease itself 1.

d) It can rarely be associated with malignancies - INCORRECT

The association between idiopathic inflammatory myopathies and malignancy is NOT rare - this is a dangerous misconception. The evidence clearly demonstrates:

High-risk associations 4:

• Dermatomyositis has a well-established, significant cancer association
• Anti-TIF1 antibodies correlate with cancer-associated dermatomyositis in adults
• Anti-NXP-2 antibodies are associated with malignancy
• The 2023 international guideline specifically addresses cancer screening protocols, indicating this is a common enough concern to warrant systematic screening 4

Cancer screening recommendations 4:

• Patients are stratified into high, moderate, and standard cancer risk categories
• Enhanced cancer screening includes CT neck/thorax/abdomen/pelvis, mammography, PSA, CA-125, and other modality-specific tests
• The guideline's existence reflects that malignancy association is clinically significant, not rare

The Mayo Clinic guideline notes that immune-mediated necrotizing myopathy "may be triggered by viral infections, medications such as statins, and malignant neoplasms" 1. The emphasis on cancer screening in modern myositis management contradicts any characterization of this association as "rare."

Clinical Implications

For polymyositis diagnosis: Look for symmetric proximal weakness with elevated CK, characteristic EMG findings, and endomysial inflammatory infiltrates with CD8+ T cells invading non-necrotic fibers 1.

For IBM recognition: Asymmetric quadriceps and finger flexor weakness in patients over 50 should trigger consideration of IBM, not polymyositis, as these conditions require completely different management approaches 2.

For cancer surveillance: All patients with dermatomyositis and those with specific high-risk antibodies require systematic cancer screening at diagnosis and during follow-up 4. This is standard of care, not an exceptional circumstance.